{"filing":{"accession_number":"0001193125-26-343421","cik":"0002114044","ticker":"COAG","company_name":"Hemab Therapeutics Holdings, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"d180684d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526343421/d180684d8k.htm"},"events":[{"id":26860,"run_id":24428,"accession_number":"0001193125-26-343421","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Hemab Therapeutics' financial results for Q2 2026 (quarter ended June 30, 2026), issued on August 11, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing quarterly financial results including cash position ($457.5M), R\u0026D expenses ($20.3M), G\u0026A expenses ($5.7M), and net loss ($24.2M or $0.80 per share), along with corporate and pipeline updates. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational progress.","company_name":"Hemab Therapeutics Holdings, Inc.","ticker":"COAG","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28138,"accession_number":"0001193125-26-343421","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Hemab Therapeutics' financial results for Q2 2026 (quarter ended June 30, 2026), issued on August 11, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing quarterly financial results including cash position ($457.5M), R\u0026D expenses ($20.3M), G\u0026A expenses ($5.7M), and net loss ($24.2M or $0.80 per share), along with corporate and pipeline updates. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:12:38.897784+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28138,"accession_number":"0001193125-26-343421","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Hemab Therapeutics' financial results for Q2 2026 (quarter ended June 30, 2026), issued on August 11, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing quarterly financial results including cash position ($457.5M), R\u0026D expenses ($20.3M), G\u0026A expenses ($5.7M), and net loss ($24.2M or $0.80 per share), along with corporate and pipeline updates. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:12:38.897784+00:00","company_name":"Hemab Therapeutics Holdings, Inc.","ticker":"COAG","filing_date":"2026-08-11"}]}